Sep 16, 2024 ·The chemopreventive benefit was limited to patients who initiatedGLP-1RAs earlier in the disease course; patients who startedGLP-1RAs after they had already progressed to cirrhosis did not have lower rates of progression tohepaticdecompensation or hepatocellular cancer.
Aug 14, 2024 ·Although it isn't aGLP-1agonist, it targets thyroid hormone receptors in theliverand is associated with improvements in the amount ofliverfat, inflammation and scarring compared to placebo.
November 6, 2025 -Emerging evidence demonstrates that GLP-1 receptor agonistsmay provide significant benefits for liver health, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty ...
As we can see from the illustration, Glp-1 Effects On Liver Function has many fascinating aspects to explore.
Feb 14, 2024 ·Wester, A. et al.Glucagon-like peptide-1receptor agonists and risk of major adverseliveroutcomes in patients with chronicliverdisease and type 2 diabetes.
GLP-1Therapies andLiverDisease: A Turning Point in Care Metabolic dysfunction–associated steatoticliverdisease (MASLD) has become the most commonlivercondition in Canada and globally, affecting one in three adults. Closely linked to obesity, type 2 diabetes, and broader metabolic health, MASLD reflects a growing public health challenge that requires coordinated, multidisciplinary ...
Weighted random-effects meta-regression was performed on potential confounders on lipid profile and liver enzyme concentrations. 12 studies were identified (12 GLP-1RA arms; 677 subjects) that showed treatment with GLP-1RA reduced alanine transaminase (ALT) concentrations (WMD = −10.14, 95%CI = [−15.84, −0.44], P < 0.001), gamma-glutamyl transferase (GGT) (WMD = −11.53, 95%CI = [−15.21,−7.85], P < 0.001), and alaline phosphatase (ALP) (WMD = −8.29, 95%CI = [−11.34, −5.24], P < 0.001).
